Find clinical trials for Lung Cancer in Boston, MA
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Lung Cancer trials near Boston, MA, USA:
This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer.The drugs inv...
Phase 2
Boston, Massachusetts, United States
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an E...
Phase 1, Phase 2
Boston, Massachusetts, United States and 1 other location
This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene.The drugs involved in...
Phase 1
Boston, Massachusetts, United States
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Boston, Massachusetts, United States and 48 other locations
chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osim ...
Phase 2
Boston, Massachusetts, United States and 17 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Boston, Massachusetts, United States and 83 other locations
Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer....
Phase 1
Boston, Massachusetts, United States and 13 other locations
This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR muta...
Phase 2
Boston, Massachusetts, United States and 1 other location
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Boston, Massachusetts, United States and 209 other locations
Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung...
Phase 1
Boston, Massachusetts, United States and 38 other locations
Clinical trials
Research sites
Resources
Legal